Tuesday☕️

Tuesday☕️

Trending:

  • On September 29, 2025, U.S. President Donald Trump presented a 20-point plan to resolve the Gaza conflict during a meeting with Israeli Prime Minister Benjamin Netanyahu at the White House, describing it as a structured approach for an immediate ceasefire, hostage releases, and long-term reconstruction, with a 72-hour deadline for Hamas to accept or face full U.S. support for Israeli operations. Key elements include establishing Gaza as a deradicalized zone posing no threat to neighbors; halting military activities upon agreement; exchanging all hostages (living and deceased) within 72 hours for Israel's release of 250 prisoners serving life sentences and 1,700 Gazans detained after October 7, 2023; offering amnesty and safe passage to Hamas members who agree to peace; allowing unrestricted aid via UN and international organizations; setting up temporary governance by a technocratic Palestinian committee overseen by a "Board of Peace" chaired by Trump and including global leaders; launching a U.S.-led economic redevelopment program with a special economic zone; demilitarizing the area through weapons decommissioning; securing commitments from regional partners; deploying an International Stabilization Force for security and Palestinian police training; phasing out IDF presence based on progress without occupation or annexation; promoting interfaith dialogue; and providing a route to Palestinian statehood after Palestinian Authority reforms, facilitated by U.S.-led negotiations. In case of Hamas delays, aid and redevelopment would advance in controlled zones.
Clickable image @RapidResponse47
  • Netanyahu supported the plan as a practical option, and Qatari and Egyptian mediators forwarded it to Hamas for consideration. A joint statement from several Arab and Islamic countries, including Saudi Arabia, Jordan, UAE, Indonesia, Pakistan, Turkey, Qatar, and Egypt, welcomed it as progress toward stability. In contrast, some Gaza residents and analysts have voiced doubts, viewing it as impractical or biased toward Israel, possibly enabling real estate projects and U.S. military involvement while overlooking key Palestinian goals. The proposal stands out from earlier ones by prioritizing U.S.-directed administration and economic measures, though its viability depends on Hamas's reply and wider endorsement, in the context of persistent regional issues, with no firm rollout steps yet outlined.

Economics & Markets:

  • Yesterday’s U.S. stock market:
TradingView
  • Yesterday’s commodity market:
TradingView @9:09 PM EST
  • Yesterday’s crypto market:
TradingView @9:09 PM EST

Health:

  • On September 29, 2025, Russia's Federal Medical-Biological Agency (FMBA) presented Enteromix, an oncolytic cancer vaccine developed by the National Medical Research Radiological Centre and the Engelhardt Institute of Molecular Biology. The vaccine utilizes four non-pathogenic enteroviruses to selectively infect and break down cancer cells while activating the patient's immune system to target tumors. Preclinical studies in animal models showed complete tumor elimination with strong safety results, including no harm to healthy tissues and fewer side effects than conventional therapies like chemotherapy or radiation. Phase I human trials, which began in June 2025 with 48 participants focused on colorectal cancer—a condition linked to over 900,000 deaths worldwide each year—have yielded initial data indicating 60-80% tumor reduction, stopped disease advancement, and extended survival times, with no major adverse reactions observed even after repeated administrations.
  • Enteromix employs viral vectors instead of mRNA technology, and the FMBA intends to make it available at no cost to patients if approved, with possible applications to other cancers such as glioblastoma and melanoma. The update was shared at the Eastern Economic Forum in Vladivostok, framing Enteromix as a candidate in the field of immunotherapies, similar to the FDA-approved Provenge for prostate cancer, which has demonstrated survival improvements in late-stage patients.

Environment & Weather:

  • On September 29, 2025, Typhoon Bualoi, after making landfall on Vietnam's central coast late the previous evening with winds up to 133 km/h, triggered severe flooding in northern regions including Việt Hồng commune in Yên Bái province, where ongoing heavy rains and storm surges have submerged homes, roads, and farmland. The situation remains active, with rescue operations underway amid risks of further landslides and flash floods. Confirmed fatalities stand at least 11 nationwide, with 17 people reported missing, primarily fishermen and residents in affected areas, while dozens more have been injured; these numbers may rise as assessments continue in hard-hit provinces like Yên Bái, Nghe An, and Quang Tri.
Clickable image @WeatherMonitors
  • The typhoon, which weakened to a tropical depression after landfall but left widespread devastation including damaged infrastructure, power outages, and evacuations of over 28,000 people, has compounded recovery efforts following recent storms in the region. Authorities have deployed military and emergency teams for relief, closed airports, and declared states of emergency in several areas, urging residents to avoid travel.
Clickable image @WeatherMonitors

Defense & Security:

  • On September 29, 2025, the U.S. Army awarded Raytheon, an RTX business, a $5.04 billion cost-plus-fixed-fee contract for the production and sustainment of Coyote Missile Systems over an eight-year period. The deal encompasses fixed and mobile launchers, kinetic and non-kinetic interceptors, and Ku-band radio frequency system radars, focusing on counter-unmanned aircraft systems capabilities. The Coyote is a low-cost, rail-launched missile designed to intercept drones, with variants that use explosive warheads or electronic warfare to neutralize threats, building on its combat-proven performance in integrated air and missile defense.
  • This contract represents a major investment in advanced missile technology to bolster U.S. defense against evolving threats like unmanned aerial systems, aligning with broader military priorities for maintaining technological superiority. It highlights ongoing commitments to enhancing operational readiness without specifying immediate applications, though it may support responses to global security challenges.

Earth Intelligence:

  • We have now launched a new version of the Earth Intelligence platform. This version can be customized to your unique needs, can integrate all your data to display and monitor your world, can be filtered to any industry or knowledge form, and can evolve with your operational needs. This version is for custom clients only but if you’d like to beta test, let us know and we can give you free access. This new platform is designed to give you unparalleled situational awareness for your industry or topics of interests.
Clickable image: Earth Intelligence Platform
  • Our free Earth Intelligence globe can still be accessed for at earthwatch.io and the new platform can be accessed by visiting earthintel.io
  • If you have any questions, email us at earthintelligence@earthintel.news

Statistic:

  • Largest public pharmaceutical companies by market capitalization:
  1. 🇺🇸 Eli Lilly:$651.28B
  2. 🇺🇸 Johnson & Johnson:$437.40B
  3. 🇺🇸 AbbVie:$394.22B
  4. 🇨🇭 Roche:$257.32B
  5. 🇩🇰 Novo Nordisk:$241.45B
  6. 🇨🇭 Novartis:$240.23B
  7. 🇬🇧 AstraZeneca:$229.84B
  8. 🇺🇸 Merck:$196.27B
  9. 🇺🇸 Amgen:$147.49B
  10. 🇺🇸 Gilead Sciences:$139.73B
  11. 🇺🇸 Pfizer:$135.60B
  12. 🇫🇷 Sanofi:$111.25B
  13. 🇺🇸 Vertex Pharmaceuticals:$101.35B
  14. 🇺🇸 CVS Health:$95.84B
  15. 🇺🇸 Bristol-Myers Squibb:$89.86B
  16. 🇬🇧 GlaxoSmithKline:$82.71B
  17. 🇯🇵 Chugai Pharmaceutical:$70.88B
  18. 🇨🇳 Jiangsu Hengrui Medicine:$64.87B
  19. 🇦🇺 CSL:$63.42B
  20. 🇺🇸 Zoetis:$63.40B
  21. 🇺🇸 Regeneron Pharmaceuticals:$59.43B
  22. 🇺🇸 Alnylam Pharmaceuticals:$58.65B
  23. 🇩🇪 Merck KGaA:$54.72B
  24. 🇧🇪 UCB:$51.26B
  25. 🇯🇵 Takeda Pharmaceutical:$46.38B

History:

  • Johnson & Johnson was founded in 1886 in New Brunswick, New Jersey, by three brothers: Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson. At a time when surgery was often deadly due to poor hygiene and infection, they were inspired by the antiseptic methods promoted by British surgeon Joseph Lister and aimed to bring sterile medical supplies to hospitals. Their early innovations included mass-produced sterile gauze, sutures, and the first commercial first aid kits. Throughout the late 19th and early 20th centuries, the company expanded into maternal health and baby care, launching products such as maternity kits and Johnson’s Baby Powder. Over time, Johnson & Johnson became a household name known not only for its medical supplies but also for consumer products like Band-Aids, Listerine, and Tylenol.
  • Throughout the 20th and into the 21st century, Johnson & Johnson expanded into pharmaceuticals and medical devices, building a vast portfolio through internal research and acquisitions like Janssen Pharmaceuticals in 1961. Its pharmaceutical division went on to develop major therapies for cancer, HIV, autoimmune disorders, and mental health. While its growth has been steady, the company has also faced scrutiny and legal challenges, including lawsuits related to talcum powder safety and its role in the opioid crisis. In 2023, Johnson & Johnson officially spun off its consumer health division into a new publicly traded company called Kenvue, allowing it to focus on its core pharmaceutical and medical technology businesses. Today, Johnson & Johnson remains one of the world’s largest and most influential healthcare companies, with more than 150 years of experience, operations in over 60 countries, and a commitment to tackling major global health issues through innovation, research, and strategic partnerships.

Image of the day:

Clickable image @earthcurated

Article:

Clickable image

Thanks for reading!

Earth is complicated, we make it simple.

Monitor the planet with the Earth Intelligence System. Click the image below to view the Earth Intelligence System:

Clickable image

Support/Suggestions Email:

earthintelligence@earthintel.news

Read more